摘要
目的探讨普罗帕酮联合前列地尔治疗心衰合并快速心律失常的疗效。方法选取2021年9月至2023年8月我院收治的100例心衰合并快速心律失常患者,按照抽签法分为两组。对照组采用前列地尔治疗,观察组采用普罗帕酮联合前列地尔治疗。比较两组的心律失常事件、血清指标、心功能指标。结果治疗后,观察组房性早搏、室性早搏、短阵室速数量及BNP、CRP水平均低于对照组,CI、LVEF高于对照组(P<0.05)。结论普罗帕酮联合前列地尔可控制心衰合并快速心律失常患者的症状,调节BNP及CRP水平,改善患者心功能。
Objective To explore the efficacy of propafenone combined with alprostadil in the treatment of heart failure complicated with tachyarrhythmia.Methods 100 patients with heart failure complicated with tachyarrhythmia admitted to our hospital from September 2021 to August 2023 were divided into two groups according to the lottery method.The control group was treated with alprostadil,and the observation group was treated with propafenone combined with alprostadil.The arrhythmia events,serum indicators and cardiac function indicators were compared between the two groups.Results After treatment,the numbers of atrial premature beat,ventricular premature beat and short ventricular tachycardia,and the BNP and CRP levels of the observation group were lower than those of the control group,and the CI and LVEF were higher than those of the control group(P<0.05).Conclusions Propafenone combined with alprostadil can control the symptoms of tachyarrhythmia,regulate the BNP and CRP levels,and improve the cardiac function of patients.
作者
刘银梅
程保玲
张淑利
LIU Yinmei;CHENG Baoling;ZHANG Shuli(The First Outpatient Department of Henan Provincial Directly Affiliated Organs,Zhengzhou 450003,China)
出处
《临床医学工程》
2024年第7期803-804,共2页
Clinical Medicine & Engineering
基金
河南省医学科技攻关计划联合共建项目(LHGJ20190855)。
